XOMA to Announce Third Quarter 2014 Financial Results and Host Webcast on November 6

BERKELEY, Calif., Oct. 27, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation XOMA, a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Thursday, November 6, 2014, at 4:30 p.m. Eastern time to discuss third quarter 2014 financial results and provide an update on gevokizumab's global clinical programs.

The webcast can be accessed via the Investors & Media section of XOMA's website at http://investors.xoma.com/events.cfm and will be available for replay until close of business on February 6, 2015. Telephone numbers for the live audiocast are 877-369-6589 (U.S./Canada) and 408-337-0122 (international).

About XOMA Corporation

XOMA's portfolio of innovative product candidates is the result of the company's focus on allosteric modulation, which offers opportunities to develop new classes of therapeutic antibodies with the potential to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with SERVIER through a global Phase 3 program in Behçet's disease uveitis and non-infectious uveitis as well as ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also produced the XMet program, which consists of three classes of antibodies, including XOMA 358, an allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling, that could have a major effect on the treatment of abnormal metabolic states.

More detailed information can be found at www.xoma.com.